Related Experiment Video

Updated: May 10, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in

C-S Hsu1, J-H Kao, Y-C Chao

  • 1Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, Taipei, Taiwan.

Alimentary Pharmacology & Therapeutics
|June 28, 2013
PubMed

Insights

Hepatitis C virus (HCV) infection increases stroke risk. However, interferon-based therapy (IBT) significantly reduces this risk in chronic hepatitis C patients, offering a potential long-term benefit.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Neurology

Background:

  • Hepatitis C virus (HCV) infection is associated with increased risks of insulin resistance and carotid atherosclerosis.
  • Understanding the link between HCV and cerebrovascular events is crucial for patient management.

Purpose of the Study:

  • To investigate the association between HCV infection and the risk of stroke.
  • To evaluate the impact of interferon-based therapy (IBT) on stroke risk in patients with chronic hepatitis C (CHC).

Main Methods:

  • A retrospective cohort study involving 3113 newly diagnosed HCV patients and 12,452 matched controls.
  • Analysis of stroke incidence using a 5-year follow-up from Taiwan's National Health Insurance Program.
  • Hazard ratios (HR) were calculated, adjusting for confounding factors, comparing HCV patients to controls and IBT-treated HCV patients to non-IBT-treated patients.

Main Results:

  • HCV infection was associated with a 23% increased risk of stroke (adjusted HR = 1.23, P = 0.008).
  • Interferon-based therapy significantly reduced stroke risk in HCV patients by 61% (adjusted HR = 0.39, P = 0.039).

Conclusions:

  • HCV infection is an independent risk factor for stroke.
  • Interferon-based therapy demonstrates a protective effect against stroke in patients with chronic HCV infection.
Abstract

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...